{
    "nct_id": "NCT04530981",
    "official_title": "A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)",
    "inclusion_criteria": "1. Patients ≥18 years of age.\n2. Patients must have a histologic diagnosis of GIST.\n3. Patients must have GIST that has progressed on or have intolerance to at least 2 lines of prior TKI therapies.\n4. Patients must have an Eastern Cooperative Oncology Group performance score of ≤ 2.\n5. If a female of childbearing potential, must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements.\n6. Adequate organ and bone marrow function.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Received prior anticancer or other investigational therapy within 28 days or 5× the half-life prior to the first dose.\n2. Prior treatment with ripretinib.\n3. Patients who have had prior repaglinide treatment within 14 days prior to Cycle 1 Day 1.\n4. History or presence of clinically relevant cardiovascular abnormalities.\n5. Gastrointestinal abnormalities including but not limited to:\n\n   * inability to take oral medication,\n   * malabsorption syndromes,\n   * requirement for intravenous alimentation.\n6. Patients who have type 1 or type 2 diabetes.",
    "miscellaneous_criteria": ""
}